南新制药跌5.69% 2020年上市募12亿元西部证券保荐

Group 1 - The core viewpoint of the news is that Nanjing Pharmaceutical (688189.SH) is currently experiencing a decline in stock price, closing at 8.78 yuan with a drop of 5.69%, resulting in a total market capitalization of 2.409 billion yuan [1] - Nanjing Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share and a total of 35 million shares issued [1] - The company raised a total of 1.223 billion yuan from its initial public offering, with a net amount of 1.135 billion yuan, exceeding the originally planned fundraising amount by 466 million yuan [1] Group 2 - The company had originally planned to raise 670 million yuan, which was intended for innovative drug research and development, marketing channel network upgrades, and to supplement working capital [1] - The total issuance costs for the initial public offering amounted to 87.6177 million yuan (excluding VAT), with the lead underwriter, Western Securities Co., Ltd., receiving a total of 71.1075 million yuan in underwriting fees (excluding VAT) [1] - In 2022, the company announced a capital reserve distribution plan, increasing its total share capital from 140 million shares to 196 million shares by distributing 0.4 shares for every share held [2] - In 2023, the company further increased its total share capital to 274.4 million shares by distributing an additional 0.4 shares for every share held [2]